We are an international biotech company committed to our goal of improving the lives of patients through innovative and differentiated antibody therapeutics.read more
Tahamtan Ahmadi, M.D., Ph.D. ā Executive Vice President and Chief Medical Officer, Head of Experimental Medicines at Genmab
Executive Bio
Dr. Ahmadi joined Genmab in 2017 and became the Executive Vice President and Chief Medical Officer, Head of Experimental Medicines effective March 1, 2021. He holds an M.D. from the University of Cologne (Germany) and a Ph.D. from the University of Freiburg (Germany) and has expertise in translational research, strategic product development, global regulatory submissions and clinical development. Prior to joining Genmab, Dr. Ahmadi was head of experimental medicine and early development oncology at Janssen and a member of the Senior Leadership Team for Oncology.
During his time at Janssen, he led the global development of daratumumab including clinical R&D and medical affairs strategy across indications and was instrumental in the clinical development and initial FDA NDA submission for Ibrutinib. Prior to joining Janssen, Dr. Ahmadi was a faculty member of the Department of Hematology and Oncology at the University of Pennsylvania. Dr. Ahmadi is an author on a number of scientific articles that have been published in journals such as NEJM, Lancet, JCO and Blood, among others.
Executive Team Culture Ratings from Genmab Employees
TOP
30%
Genmab's Executive Team scores in the Top 30% of similar sized companies on Comparably